Sunday, June 18, 2017 9:25:08 PM
https://www.dropbox.com/s/myt5h9oj0fjgzt5/Summary%20Judgment%20motions%20denied%202017-1.pdf?dl=0
The memo is a good refresher on the long and tortuous history of this litigation.
Amphastar sought summary judgment on the grounds of invalidity and non-infringement, whereas Momenta sought summary judgment dismissing Amphastar's equitable defenses (as well as a separate trial) relating to Momenta's behavior surrounding the circumstances under which Momenta's patented test came to be listed in the United States Pharmacopeia (“USP"), e.g., Momenta and it's employee Dr. Shriver failed to disclose Momenta's pending patent application for the test.
I have to say that reading the description of the equitable defense, Momenta's behavior seems a bit dicey.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM